Expression of NF-κB (p65), COX-2, and pSTAT3 in PBMC derived from patients with pancreatic cancer by immunohistochemical staining
Patient no. | NF-κB (p65)* | NF-κB (p65)† | COX-2* | COX-2† | pSTAT3* | pSTAT3† |
---|---|---|---|---|---|---|
3 | 66 | 84 | 52 | 36 | 12 | 5 |
4 | 71 | 59 | 84 | 41 | 36 | 8 |
5 | 73 | — | 70 | — | 42 | — |
7 | 86 | 63 | 73 | 57 | 56 | 48 |
8 | 58 | 76 | 68 | 38 | 27 | 9 |
10 | 65 | — | 52 | — | 43 | — |
12 | 64 | — | 78 | — | 30 | — |
13 | 78 | 52 | 61 | 48 | 58 | 21 |
14 | 69 | — | 74 | — | 32 | — |
15 | 83 | — | 59 | — | 21 | — |
16 | 78 | 82 | 56 | 79 | 52 | 32 |
17 | 83 | 61 | 53 | 24 | 47 | 14 |
18 | 86 | — | 66 | — | 48 | — |
20 | 87 | 74 | 48 | 28 | 53 | 18 |
21 | 62 | 38 | 69 | 32 | 22 | 25 |
22 | 76 | 69 | 44 | 64 | 39 | 31 |
23 | 48 | — | 56 | — | 17 | — |
24 | 67 | — | 58 | — | 36 | — |
25 | 59 | — | 64 | — | 48 | — |
NOTE: Mean ± SD for p65, COX-2, and pSTAT3 pretreatment and posttreatment are 74.50 ± 10.00 and 65.80 ± 14.20 (P = 0.131), 60.80 ± 12.53 and 44.7 ± 17.37 (P = 0.029), and 40.20 ± 15.76 and 21.10 ± 13.30 (P = 0.009), respectively.
↵* Percentage of positive cells before treatment (by immunohistochemistry; an average of 300 cells was counted to make this determination).
↵† Percentage of positive cells after treatment (by immunohistochemistry; an average of 300 cells was counted to make this determination).